Drug Trial Radar · NCT07379580
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Feb 20, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Coalition for Epidemic Preparedness Innovations
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Conditions
- Mpox (Monkeypox)
- Smallpox
- Orthopoxvirus Infection
Interventions
BNT166aBiological
Intramuscular injection. Injections should be given in the deltoid muscle, using the same non-dominant arm for all IMP doses.
PlaceboOther
Intramuscular injection. Injections should be given in the deltoid muscle, using the same non-dominant arm for all IMP doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number (and percentage) of participants with at least one solicited local reaction (pain, erythema/redness, induration/swelling)Time frame: For up to 7 days following each dose
- Number (and percentage) of participants with at least one solicited systemic reaction (fever, headache, fatigue/tiredness, muscle pain/myalgia, joint pain/arthralgia, chills, diarrhea, vomiting)Time frame: For up to 7 days following each dose
- Number (and percentage) of participants with at least one use of antipyretics/analgesicsTime frame: For up to 7 days following each dose
- Number (and percentage) of participants with at least one unsolicited adverse event (AE) (post-Dose 1)Time frame: From Dose 1 to 28 days post-Dose 1
- Number (and percentage) of participants with at least one unsolicited AE (post-Dose 2)Time frame: From Dose 2 to 28 days post-Dose 2
- Number (and percentage) of participants with at least one serious adverse eventTime frame: From Dose 1 until the end of study, i.e., up to ~14 months
- Number (and percentage) of participants with at least one AE of special interestTime frame: From Dose 1 until the end of study, i.e., up to ~14 months
- Number (and percentage) of participants with at least one medically attended AETime frame: From Dose 1 until the end of study, i.e., up to ~14 months
- Number (and percentage) of participants with at least one AE leading to a participant's withdrawal from the studyTime frame: From Dose 1 until the end of study, i.e., up to ~14 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of Kinshasa UNIKIN
Kinshasa, Democratic Republic of the Congo · Recruiting
Institute National de Recherche Biomedicale
Kinshasa, Democratic Republic of the Congo · Recruiting
TASK Applied Science
Cape Town, South Africa · Recruiting
TREAD Research Pty Ltd
Cape Town, South Africa · Recruiting
Desmond Tutu Health Foundation Masiphumelele Clinic
Cape Town, South Africa · Recruiting
Perinatal HIV Research Unit
Johannesburg, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.